Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage

Sean Yates, Ravi Sarode

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.

Original languageEnglish (US)
JournalCurrent Neurology and Neuroscience Reports
Volume15
Issue number1
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Cerebral Hemorrhage
Anticoagulants
Intracranial Hemorrhages
Vitamin K
Therapeutics
Heparin
Guidelines
Physicians
Mortality
Incidence

Keywords

  • Anticoagulants
  • Apixaban
  • Dabigatran
  • Intracerebral hemorrhage
  • Prothrombin complex concentrate
  • Rivaroxaban
  • Target-specific oral anticoagulants
  • Vitamin K
  • Warfarin

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage. / Yates, Sean; Sarode, Ravi.

In: Current Neurology and Neuroscience Reports, Vol. 15, No. 1, 2015.

Research output: Contribution to journalReview article

@article{78d445d42dd54394b39d5d4bcc478bed,
title = "Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage",
abstract = "Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.",
keywords = "Anticoagulants, Apixaban, Dabigatran, Intracerebral hemorrhage, Prothrombin complex concentrate, Rivaroxaban, Target-specific oral anticoagulants, Vitamin K, Warfarin",
author = "Sean Yates and Ravi Sarode",
year = "2015",
doi = "10.1007/s11910-014-0504-2",
language = "English (US)",
volume = "15",
journal = "Current Neurology and Neuroscience Reports",
issn = "1528-4042",
publisher = "Current Medicine Group",
number = "1",

}

TY - JOUR

T1 - Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage

AU - Yates, Sean

AU - Sarode, Ravi

PY - 2015

Y1 - 2015

N2 - Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.

AB - Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.

KW - Anticoagulants

KW - Apixaban

KW - Dabigatran

KW - Intracerebral hemorrhage

KW - Prothrombin complex concentrate

KW - Rivaroxaban

KW - Target-specific oral anticoagulants

KW - Vitamin K

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84926245946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926245946&partnerID=8YFLogxK

U2 - 10.1007/s11910-014-0504-2

DO - 10.1007/s11910-014-0504-2

M3 - Review article

C2 - 25407132

AN - SCOPUS:84926245946

VL - 15

JO - Current Neurology and Neuroscience Reports

JF - Current Neurology and Neuroscience Reports

SN - 1528-4042

IS - 1

ER -